ERBB2 and breast cancer: Given that this and other preclinical trials have shown that combination treatment of the dual mTOR inhibitor TAK-228 with trastuzumab is more potent in treating HER2-positive breast cancers than either agent alone, it is hoped that in the coming years, we will see clinical trials that comprehensively translate the biology of these cancers and subsequently explore targeted therapy strategies.